1. Home
  2. ITCI
  3. ITCI News

Latest Intra-Cellular Therapies Inc. (ITCI) News on March 13, 2025

Intra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025
ITCI

Insider Monkey

12 days ago

Intra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025

ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
ITCI

Zacks

17 days ago

ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

ITCI

MT Newswires

17 days ago

Mizuho Downgrades Intra-Cellular Therapies to Neutral From Outperform, Lowers Price Target to $132 From $140

Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
ITCI

Zacks

20 days ago

Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates

ITCI

Associated Press Finance

20 days ago

Intra-Cellular: Q4 Earnings Snapshot

ITCI

MT Newswires

20 days ago

Intra-Cellular Therapies Q4 Net Loss Narrows, Revenue Rises

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
ITCI

GlobeNewswire

20 days ago

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

Steady M&A Deals to Begin 2025, Disappointing IPOs So Far
ITCI

GuruFocus.com

a month ago

Steady M&A Deals to Begin 2025, Disappointing IPOs So Far

ITCI

MT Newswires

a month ago

UBS Adjusts Price Target on Intra-Cellular Therapies to $132 From $87, Maintains Neutral Rating

ITCI

MT Newswires

a month ago

Canaccord Genuity Downgrades Intra-Cellular Therapies to Hold From Buy, Adjusts Price Target to $132 From $119

Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now
ITCI

Insider Monkey

2 months ago

Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now

Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now
ITCI

Insider Monkey

2 months ago

Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now

Biotech Venture Investors Optimistic, But Uncertainties Persist
ITCI

The Wall Street Journal

2 months ago

Biotech Venture Investors Optimistic, But Uncertainties Persist

Johnson & Johnson (JNJ) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
ITCI

GuruFocus.com

2 months ago

Johnson & Johnson (JNJ) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk
ITCI

Yahoo Finance

2 months ago

Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk

Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
ITCI

Yahoo Finance

2 months ago

Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings

ITCI

MT Newswires

2 months ago

RBC Downgrades Intra-Cellular Therapies to Sector Perform From Outperform on Proposed Sale to Johnson & Johnson

Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week’s Rally
ITCI

Insider Monkey

2 months ago

Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week’s Rally

Jim Cramer on Intra-Cellular Therapies, Inc. (ITCI): ‘Intra-Cellular Had Something’
ITCI

Insider Monkey

2 months ago

Jim Cramer on Intra-Cellular Therapies, Inc. (ITCI): ‘Intra-Cellular Had Something’

Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
ITCI

Zacks

2 months ago

Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales

J&J's AAA Rating in Jeopardy as Acquisition Sparks Debt Concerns
ITCI

GuruFocus.com

2 months ago

J&J's AAA Rating in Jeopardy as Acquisition Sparks Debt Concerns

J&J’s Top Rating at Risk Because of Intra-Cellular Deal
ITCI

Bloomberg

2 months ago

J&J’s Top Rating at Risk Because of Intra-Cellular Deal

The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular
ITCI

Zacks

2 months ago

The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular

JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference
ITCI

Zacks

2 months ago

JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference

J&J to leverage Intra-Cellular Therapies’ neurology portfolio
ITCI

Pharmaceutical Technology

2 months ago

J&J to leverage Intra-Cellular Therapies’ neurology portfolio

Why Intra-Cellular (ITCI) Led the Monday Upsurge?
ITCI

Insider Monkey

2 months ago

Why Intra-Cellular (ITCI) Led the Monday Upsurge?

ITCI Poised for Turnaround Amid Rising Mental Health Concerns
ITCI

GuruFocus.com

2 months ago

ITCI Poised for Turnaround Amid Rising Mental Health Concerns

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer
ITCI

Zacks

2 months ago

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer

ITCI

MT Newswires

2 months ago

Piper Sandler Downgrades Intra-Cellular Therapies to Neutral From Overweight, Adjusts Price Target to $132 From $107

Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?
ITCI

Zacks

2 months ago

Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?

ITCI Stock Surges 34% as J&J Reveals $14.6 Billion Acquisition Plan
ITCI

GuruFocus.com

2 months ago

ITCI Stock Surges 34% as J&J Reveals $14.6 Billion Acquisition Plan

JPMorgan Healthcare Conference: AI, billion-dollar deals
ITCI

Yahoo Finance Video

2 months ago

JPMorgan Healthcare Conference: AI, billion-dollar deals

These Stocks Are Moving the Most Today: Micron, Intra-Cellular Therapies, and More
ITCI

Barrons.com

2 months ago

These Stocks Are Moving the Most Today: Micron, Intra-Cellular Therapies, and More

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug
ITCI

Investor's Business Daily

2 months ago

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug

Johnson & Johnson Strikes $14.6 Billion Deal to Acquire Intra-Cellular Therapies
ITCI

MT Newswires

2 months ago

Johnson & Johnson Strikes $14.6 Billion Deal to Acquire Intra-Cellular Therapies

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal
ITCI

Investor's Business Daily

2 months ago

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal

Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B
ITCI

Investopedia

2 months ago

Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B

ITCI

MT Newswires

2 months ago

Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion

Update: Johnson & Johnson acquires Intra-Cellular Therapies
ITCI

Pharmaceutical Technology

2 months ago

Update: Johnson & Johnson acquires Intra-Cellular Therapies

ITCI

MT Newswires

2 months ago

Market Chatter: Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion

Johnson & Johnson to Acquire Intra-Cellular in $14.6 Billion Deal
ITCI

The Wall Street Journal

2 months ago

Johnson & Johnson to Acquire Intra-Cellular in $14.6 Billion Deal

RBC buyers of Intra-Cellular after ‘more favorable-than-expected’ settlement
ITCI

TipRanks

2 months ago

RBC buyers of Intra-Cellular after ‘more favorable-than-expected’ settlement

ITCI

GuruFocus.com

2 months ago

Intra-Cellular Therapies Stock Soars 19% After Securing Major Patent Victory Over Sandoz

ITCI

MT Newswires

2 months ago

Update: Intra-Cellular Therapies, Sandoz Settle CAPLYTA Patent Litigation

ITCI

MT Newswires

2 months ago

Intra-Cellular Therapies, Sandoz Settle CAPLYTA Patent Litigation

Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz
ITCI

GlobeNewswire

2 months ago

Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz

ITCI

MT Newswires

2 months ago

RBC Trims Price Target on Intra-Cellular Therapies to $108 From $112, Keeps Outperform Rating

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ITCI

GlobeNewswire

2 months ago

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Turn A Profit?
ITCI

Simply Wall St.

2 months ago

When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Turn A Profit?

Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting
ITCI

GlobeNewswire

3 months ago

Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting

ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
ITCI

Zacks

3 months ago

ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD

ITCI

MT Newswires

3 months ago

Intra-Cellular Therapies Files Supplemental NDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder

Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
ITCI

GlobeNewswire

3 months ago

Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy

Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?
ITCI

Zacks

3 months ago

Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?

How Intra-Cellular surprised Wall Street by breaking character
ITCI

BioPharma Dive

4 months ago

How Intra-Cellular surprised Wall Street by breaking character

ITCI

MT Newswires

4 months ago

UBS Raises Price Target on Intra-Cellular Therapies to $87 From $79, Maintains Neutral Rating

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
ITCI

GlobeNewswire

4 months ago

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

ITCI

MT Newswires

4 months ago

Intra-Cellular Therapies Insider Sold Shares Worth $3,692,100, According to a Recent SEC Filing

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
ITCI

GlobeNewswire

4 months ago

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress

Intra-Cellular bolsters Caplyta data with another Phase III win
ITCI

Pharmaceutical Technology

4 months ago

Intra-Cellular bolsters Caplyta data with another Phase III win

Intra-Cellular bolsters Caplyta data with another Phase III win
ITCI

Clinical Trials Arena

4 months ago

Intra-Cellular bolsters Caplyta data with another Phase III win

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia
ITCI

GlobeNewswire

4 months ago

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia

Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results
ITCI

Simply Wall St.

4 months ago

Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results

Intra-Cellular Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
ITCI

Simply Wall St.

4 months ago

Intra-Cellular Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

ITCI

GuruFocus.com

4 months ago

Intra-Cellular Therapies Inc (ITCI) Q3 2024 Earnings Call Highlights: Robust Sales Growth and ...

ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
ITCI

Zacks

4 months ago

ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
ITCI

Zacks

4 months ago

Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates

ITCI

MT Newswires

4 months ago

Intra-Cellular Therapies Posts Unchanged Q3 Net Loss, Revenue Rises

ITCI

Associated Press Finance

4 months ago

Intra-Cellular: Q3 Earnings Snapshot

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
ITCI

GlobeNewswire

4 months ago

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance

What To Expect From Intra-Cellular Therapies Inc (ITCI) Q3 2024 Earnings
ITCI

GuruFocus.com

4 months ago

What To Expect From Intra-Cellular Therapies Inc (ITCI) Q3 2024 Earnings

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
ITCI

Zacks

5 months ago

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
ITCI

GlobeNewswire

5 months ago

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds
ITCI

Insider Monkey

5 months ago

Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
ITCI

Zacks

5 months ago

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe

ITCI

MT Newswires

5 months ago

Morgan Stanley Raises Price Target on Intra-Cellular Therapies to $95 From $92, Keeps Overweight Rating

JPMorgan Chase & Co's Strategic Acquisition of Shares in Intra-Cellular Therapies Inc
ITCI

GuruFocus.com

5 months ago

JPMorgan Chase & Co's Strategic Acquisition of Shares in Intra-Cellular Therapies Inc

ITCI

MT Newswires

5 months ago

RBC Lifts Price Target on Intra-Cellular Therapies to $108 From $106, Keeps Outperform Rating

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
ITCI

GlobeNewswire

6 months ago

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress

Intra-Cellular Therapies (NASDAQ:ITCI) delivers shareholders fantastic 54% CAGR over 5 years, surging 3.9% in the last week alone
ITCI

Simply Wall St.

6 months ago

Intra-Cellular Therapies (NASDAQ:ITCI) delivers shareholders fantastic 54% CAGR over 5 years, surging 3.9% in the last week alone

Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
ITCI

Zacks

6 months ago

Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?

ITCI

MT Newswires

6 months ago

Piper Sandler Upgrades Intra-Cellular Therapies to Overweight From Neutral, $92 Price Target

Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now
ITCI

Insider Monkey

6 months ago

Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now

ITCI

MT Newswires

6 months ago

Intra-Cellular Therapies Insider Sold Shares Worth $5,089,236, According to a Recent SEC Filing

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
ITCI

GlobeNewswire

6 months ago

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences

ITCI

MT Newswires

7 months ago

Intra-Cellular Therapies Insider Sold Shares Worth $9,086,738, According to a Recent SEC Filing

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
ITCI

Simply Wall St.

7 months ago

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon
ITCI

Investor's Business Daily

7 months ago

Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon

ITCI

MT Newswires

7 months ago

UBS Adjusts Price Target on Intra-Cellular Therapies to $79 From $83, Maintains Neutral Rating

Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
ITCI

Zacks

7 months ago

Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
ITCI

GlobeNewswire

7 months ago

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

ITCI

MT Newswires

7 months ago

RBC Trims Price Target on Intra-Cellular Therapies to $106 From $107, Keeps Outperform Rating

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
ITCI

Investor's Business Daily

7 months ago

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'

ITCI

MT Newswires

7 months ago

Intra-Cellular Therapies Appoints Sanjeev Narula CFO

Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
ITCI

Zacks

7 months ago

Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates

ITCI

MT Newswires

7 months ago

Intra-Cellular Therapies Q2 Net Loss Narrows, Revenue Rises

ITCI

Associated Press Finance

7 months ago

Intra-Cellular: Q2 Earnings Snapshot

Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
ITCI

GlobeNewswire

7 months ago

Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer

Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
ITCI

GlobeNewswire

7 months ago

Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance

Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
ITCI

Zacks

7 months ago

Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Share on Social Networks: